TT-10 for Advanced Cancer

Recruiting in Palo Alto (17 mi)

+8 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: Portage Biotech

No Placebo Group

Trial Summary

What is the purpose of this trial?This trial tests a new oral drug, TT-10, for safety and effectiveness in people with severe cancers that did not improve with usual treatments. The goal is to determine a safe dosage and see if it can help control tumor growth.

Eligibility Criteria

Adults with advanced solid tumors like oral, head and neck, kidney, prostate or lung cancer who've not responded to standard treatments can join. They must have a life expectancy over 3 months, good blood and organ function, and be able to consent. Some need accessible tumors for biopsies.

Inclusion Criteria

My liver is functioning well.

My kidney function is within normal ranges.

I am 18 years old or older.

+13 more

Exclusion Criteria

I have not had radiotherapy in the last 2 weeks.

I have a history of hepatitis C.

I have not had any cancer treatment in the last 4 weeks.

+16 more

Participant Groups

The trial is testing TT-10's safety when taken orally by patients with certain advanced cancers. It aims to find the highest dose patients can tolerate without severe side effects (MTD) or the suggested dose for future Phase 2 trials (RP2D).

1Treatment groups

Experimental Treatment

Group I: Multiple Ascending DoseExperimental Treatment1 Intervention

3+3 Dose escalation until MTD and/or R2PD of TT-10 is determined